Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. We are transforming patient care by providing critical insights into what drives disease through our advanced blood and tissue tests, real-world data and AI analytics. Our tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Business segments
Q2 2026 · $335.0MThe company’s own SEC segment disclosure.
- Oncology$219.1M65%
- Biopharma Data$60.9M18%
- Screening$52.9M16%
- Licensing Other$2.1M1%
Guardant Health, Inc. (GH) reported revenue of $335M in Q2 2026 (quarter ended Jun 30, 2026), up 44% from the same quarter a year earlier. That came with a gross margin of 65% and net loss of $120M. For the full year FY2025, revenue was $982M (+33% year on year) and net income −$416M. Its largest product in Q2 2026 was Oncology at $219M, 65% of the disclosed total, well ahead of Biopharma Data at 18%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #4 of 17 by Smart Score